433
Participants
Start Date
October 19, 2015
Primary Completion Date
November 6, 2020
Study Completion Date
April 1, 2026
Tremelimumab
Tremelimumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.
Durvalumab
Durvalumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.
Bevacizumab
Bevacizumab 15 mg/kg will be administered by IV infusion every 3 weeks until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurred first.
Research Site, Taipei
Research Site, Taoyuan
Research Site, New York
Research Site, Stony Brook
Research Site, Seongnam-si
Research Site, Córdoba
Research Site, Philadelphia
Research Site, Philadelphia
Research Site, Milan
Research Site, Durham
Research Site, Pamplona
Research Site, Jacksonville
Research Site, Tampa
Research Site, Nashville
Research Site, Junggu
Research Site, Indianapolis
Research Site, Busan
Research Site, Dallas
Research Site, Benevento
Research Site, Kaohsiung City
Research Site, Phoenix
Research Site, San Francisco
Research Site, Portland
Research Site, Seattle
Research Site, Singapore
Research Site, Bukit Merah
Research Site, Shanghai
Research Site, Nanjing
Research Site, Singapore
Research Site, Hangzhou
Research Site, New Haven
Research Site, Boston
Research Site, Hong Kong
Research Site, Shatin
Research Site, Roma
Research Site, Chūōku
Research Site, Kashiwa
Research Site, Osakasayama-shi
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Barcelona
Research Site, Barcelona
Lead Sponsor
MedImmune LLC
INDUSTRY